PMA device
WRAPSODY® Cell-Impermeable Endoprosthesis
Merit Medical Systems, Inc. · System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV, Class III) · First FDA decision Dec 19, 2024, newest Dec 11, 2025Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
1
Naming "WRAPSODY Cell-Impermeable Endoprosthesis"
MAUDE reports
0
Brand "WRAPSODY Cell-Impermeable Endoprosthesis", since 2015
PubMed studies
9
Mentioning "WRAPSODY Cell-Impermeable Endoprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing WRAPSODY® Cell-Impermeable Endoprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 4 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Hemodialysis for Treatment of SchizophreniaNational determinationOn the books130.8Updated Dec 2, 2002
- Dialysis Access MaintenanceLocal determinationIn effectL34062CGS Administrators, LLCUpdated Feb 20, 2026
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
- Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower ExtremitiesLocal determinationIn effectL36377First Coast Service Options, Inc.Updated Nov 21, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "WRAPSODY Cell-Impermeable Endoprosthesis", any status and sponsor, newest update first.
- WRAP North AmericaRecruiting
Merit Medical Systems, Inc.Public (MMSI)
NCT06807099 · 250 participants (planned) · Start Jul 31, 2025 · Primary completion Dec 2027
Device: Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE) · For: Venous Stenosis; Venous Occlusion
Sites: Dothan, Alabama; Phoenix, Arizona; Riverside, California · 16 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "WRAPSODY Cell-Impermeable Endoprosthesis", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PFV
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "WRAPSODY Cell-Impermeable Endoprosthesis"[tiab]. The summary above synthesizes these.
- Use of the Wrapsodyࡊ Cell-Impermeable Endoprosthesis for the treatment of pelvic congestion syndrome due to nutcracker syndrome.
Tkabladze E, Büchner KJ · CVIR Endovasc · 2026Letter
- Patency rates following treatment with the WRAPSODYࡊ Cell-Impermeable Endoprosthesis for recalcitrant renal access circuit dysfunction: Results from a tertiary Australian centre.
Bond RG, Arasu R, Jantzen TM, et al. · Vascular · 2025
- First Clinical Results of the Merit WRAPSODYࡊ Cell-Impermeable Endoprosthesis for Treatment of Access Circuit Stenosis in Haemodialysis Patients.
Gilbert J, Rai J, Kingsmore D, et al. · Cardiovasc Intervent Radiol · 2021Observational Study
- First Clinical Results of the Merit WRAPSODYࡊ Cell-Impermeable Endoprosthesis for Treatment of Access Circuit Stenosis in Haemodialysis Patients.
Gilbert J, Rai J, Kingsmore D, et al. · Cardiovasc Intervent Radiol · 2021Letter
- Prospective, Multicenter, Observational Study to Evaluate a Cell-Impermeable Endoprosthesis for Treatment of Stenosis or Occlusion within the Dialysis Outflow Circuit of an Arteriovenous (AV) Fistula or AV Graft (The WRAP Registry).
Rajan DK, Kitrou PM · Cardiovasc Intervent Radiol · 2023Observational Study, Multicenter Study
- Safety and Effectiveness of the Wrapsody Cell-Impermeable Endoprosthesis to Treat Dysfunctional Arteriovenous Grafts: Results from the Nonrandomized Arm of the WAVE Trial.
Razavi MK, Balamuthusamy S, Makris AN, et al. · J Vasc Interv Radiol · 2026Clinical Trial, Multicenter Study
- Letter to the Editor Regarding "First Clinical Results of the Merit WRAPSODY Cell-Impermeable Endoprosthesis for Treatment of Access Circuit Stenosis in Haemodialysis Patients" published by Gilbert et al.
Bream PR, Chick JFB, Lessne ML · Cardiovasc Intervent Radiol · 2021Letter, Comment
- Use of Alternative Endograft for Popliteal Artery Aneurysm Endovascular Repair: A Single Center Experience in Italy With the Wrapsodyࡊ Cell-Impermeable Endoprosthesis.
Marazzi G, Udini M, Oggianu C, et al. · Ann Vasc Surg · 2026
- One-Year Clinical Outcomes from the Randomized Controlled Arm of the Wrapsody Arteriovenous Access Efficacy (WAVE) Trial.
Razavi MK, Balamuthusamy S, Makris AN, et al. · J Vasc Interv Radiol · 2026Equivalence Trial, Multicenter Study
Other devices of this type
Also filed under product code PFV.
- GORE VIABAHN Endoprosthesis with Heparin Bioactive SurfaceW. L. Gore & Associates, Inc. · PMA 2022
- Covera Vascular Covered StentC.R. Bard, Inc. · PMA 2022
- Fluency Plus Endovascular Stent GraftBard Peripheral Vascular, Inc. · PMA 2017
- Flair Endovascular Stent GraftBard Peripheral Vascular · PMA 2014
- Bard Flair Endovascular Stent GraftBard Peripheral Vascular · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.